Near-infrared Radiation-transcranial Photobiomodulation for Major Depressive Disorder

Sponsor
China Medical University Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT04619121
Collaborator
Ministry of Science and Technology, Taiwan (Other)
64
1
2
19.3
3.3

Study Details

Study Description

Brief Summary

This study was designed to be a 3 year, 3 phases project, and will explore the therapeutic effects from near-infrared transcranial photobiomodulation (NIR tPBM) in major depressive disordered human subjects, and it's biological mechanisms in cellular and animal model. However, due to shortage of funding under the pandemics, the project is now modified to start from its clinical part first, and will continue to its basic parts later when funding resources in place.

Condition or Disease Intervention/Treatment Phase
  • Device: NIR-tPBM
  • Device: Sham device
N/A

Detailed Description

Major depressive disorder (MDD) is a leading cause of the overall global burden of disease in modern society, and has been estimated to move into the first place by 2030. Current antidepressants and psychotherapy had proved their efficacy, but are limited by the adverse effects and shortage of capable therapists worldwide. Accumulating evidence showed that hypometabolism of global and specific brain regions, inflammation, oxidative stress, suppression of neurogenesis and disturbed circadian rhythm all contribute to the pathophysiology of MDD.

Dr. Paolo Cassano, MD, PhD and his team from the Massachusetts General Hospital (MGH) of Harvard University recently demonstrated in both animal and human subjects that near-infrared radiation-transcranial photobiomodulation (NIR-tPBM) is a well-tolerated and effective treatment modality for MDD, and hypothesized NIR-tPBM may activate brain metabolism, be anti-inflammatory, reduce oxidative stress and promote neurogenesis. So far, the clinical studies are either open-labeled or only of small scale (n=21), and the real antidepressant mechanism of NIR-tPBM has not yet been fully understood. Adequately powered, well designed, double-blind randomized-control trials of larger scale is in pressing need.

In this 3-year study, we will collaborate with the team from Harvard University and MGH, to comprehensively evaluate from cellular mechanism, animal model, to clinical trials in human, the underlying mechanism of NIR-tPBM and the clinical strategy of NIR-tPBM. In the cellular study, we will culture and treat the human neuron-like cell lines with continuous NIR-PBM of different dosimetry and different duration, and compare the differences in cellular circadian rhythm, energy metabolism, and inflammation markers as well as the underlying gene expression. In the animal study, the mice under chronic stress environment will be treated with NIR-tPBM of different duration. We will compare the behavioral differences relevant to anxiety, depression and cognitive performance, as well as the differences in neurogenesis, neuroplasticity, energy metabolism, circadian rhythm, and inflammation markers of the mice and the gene expression of the biomarkers. In both cellular and animal studies, dose-response assessment will be applied. In the clinical human study, we will conduct a prospective, double-blind, randomized, sham-controlled trial, recruiting totally 80 MDD patients, age 18 to 75, and apply adjunctive NIR t-PBM to the dorsolateral prefrontal cortex, bilaterally and simultaneously, from 20 minutes and up to 80 minutes a day under the evaluation and recommendation of the clinicians, for 8 consecutive weeks. The change in depressive symptoms and circadian behaviors will be recorded in the 0, 2, 4, 8, 12 weeks and compared. The patient's peripheral blood-based biochemistry profile, inflammatory, oxidative stress, and circadian rhythm markers, as well as the gene expression of the relevant markers, will be collected in week 0, 8, and 12, and be compared.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
64 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Near-infrared Radiation-transcranial Photobiomodulation for Major Depressive Disorder: From Cellular, Animal Studies to a Sham-controlled Double-blind Randomized Clinical Trial
Actual Study Start Date :
Dec 21, 2020
Actual Primary Completion Date :
May 31, 2022
Anticipated Study Completion Date :
Jul 31, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Treatment with real NIR-tPBM on top of standing pharmacotherapy

NIR t-PBM to the dorsolateral prefrontal cortex, bilaterally and simultaneously, from 20 minutes to 80 minutes a day, for 8 consecutive weeks.

Device: NIR-tPBM
The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.
Other Names:
  • near-infrared transcranial photobiomodulation
  • Sham Comparator: Sham device on top of standing pharmacotherapy

    Sham device with neglectable energy to the dorsolateral prefrontal cortex, bilaterally and simultaneously, from 20 minutes to 80 minutes a day, for 8 consecutive weeks.

    Device: Sham device
    The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
    Other Names:
  • Sham
  • Outcome Measures

    Primary Outcome Measures

    1. Change in depressive symptoms (subjective) [Measured biweekly up to 12 weeks.]

      Measured with Beck Depression Rating scale, value from 0 to 63, with higher scores indicating greater severity of depression.

    2. Change in depressive symptoms (objective) [Measured biweekly until trial completed, up to 12 weeks.]

      Measured with Hamilton Depression rating scale (21-items), value from 0 to 66, with higher scores indicating greater severity of depression.

    Secondary Outcome Measures

    1. Change in circadian rhythm [Measured biweekly up to 12 weeks.]

      Measured with Munich ChronoType Questionnaire (MCTQ), value of 16 to 86. It offers methods to make up for sleep log, and measures the behavioral change around the clock.

    2. Change in sleep quality [Measured twice a week up to 12 weeks.]

      Measured with Pittsburgh Sleep Quality Index,value of 0 to 21, provides a subjective measure of sleep quality and patterns. The higher the score, the worse the quality.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Subjects may be included in the study only if they meet all of the following criteria:
    1. The subject should be between at least 18 years of age at screening, but has not had their 76th birthday at screening.

    2. Diagnosis of major depressive disorder (Based on Diagnostic Statistical Manual-IV or 5 ; diagnosis code: 296.22-296.23、296.32-296.33).

    3. HAM-D-17 ≥14 and ≤ 25

    4. Subject Informed Consent obtained in writing in compliance with local regulations prior to enrollment into this study.

    5. The subject (and caregiver, if applicable) is willing to participate in this study for at least 12 weeks.

    6. Subjects may only be taking one (1) antidepressant, and will need to be on a stable dose for at least four weeks prior to enrollment.

    Exclusion Criteria:
    • Subjects will be excluded from the study for any of the following reasons:
    1. The subject is pregnant or lactating.

    2. The subject failed two or more FDA-approved antidepressants during current episode.

    3. Structured psychotherapy focused on treating the subject's depression is exclusionary unless the subject has had at least 8 weeks of treatment prior to the screening visit.

    4. Substance used disorder in the past 6 months.

    5. Psychotic disorder or psychotic episode (current psychotic episode per assessment).

    6. Bipolar affective disorder (per assessment).

    7. Unstable or active medical illness.

    8. Active suicidal or homicidal ideation.

    9. The subject has a significant skin condition (i.e., hemangioma, scleroderma, psoriasis, rash, open wound or tattoo) on the subject's scalp that is found to be directly below any of the procedure sites.

    10. The subject has an implant of any kind in the head (e.g. stent, clipped aneurysm, embolized AVM, implantable shunt - Hakim valve).

    11. Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study enrollment.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 China Medical University Beigang Hospital Beigang Yunlin County Taiwan 651012

    Sponsors and Collaborators

    • China Medical University Hospital
    • Ministry of Science and Technology, Taiwan

    Investigators

    • Principal Investigator: Ta-Wei Guu, MD, China Medical University, Taiwan

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Ta-wei Guu, Attending physician, China Medical University Hospital
    ClinicalTrials.gov Identifier:
    NCT04619121
    Other Study ID Numbers:
    • CMUH109-REC3-054
    First Posted:
    Nov 6, 2020
    Last Update Posted:
    Jul 19, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Ta-wei Guu, Attending physician, China Medical University Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 19, 2022